AbsoluteDx™
Comprehensive clinical genetic test combining monogenic and polygenic risk assessment
Software · Cloud SaaSCompany source
Company profile
About Allelica
Allelica is a precision medicine company specializing in polygenic risk score (PRS) analysis and clinical genomic risk assessment for common diseases. The company offers state-of-the-art tools designed to integrate genetics into clinical practice to reduce the burden of cardiovascular disease, breast cancer, Alzheimer's disease, and other conditions. Allelica's multi-ancestry PRS technology is validated and calibrated for people of diverse ancestry and admixed backgrounds, using thousands to millions of genetic variants across the whole genome to provide comprehensive disease risk modeling. The company serves three primary markets: physicians seeking to provide cutting-edge personalized risk assessments, clinical laboratories looking to bring advanced genomic testing in-house, and pharmaceutical/biotech companies optimizing clinical trial stratification. Allelica's product portfolio includes clinical tests like AbsoluteDx™ and Breast Risk Reveal™, software platforms including PREDICT and DISCOVER & VALIDATE, and the Allelica Precision Server for on-premises bioinformatics analysis. The platform enhances traditional care by combining polygenic risk scores with standard clinical risk models, enabling identification of high-risk patients who may be missed by conventional screening methods. Allelica's PRS technology has been recognized in the 2026 ACC/AHA cardiovascular risk assessment guidelines and is deployed through partnerships with leading health systems, laboratories, and research institutions globally.
Company description Allelica official website
Primary marketPrecision Medicine & Genomics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Allelica?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Alzheimer's disease
- Breast cancer
- Cardiovascular disease
- Childhood neuropsychiatric disorders
- Common diseases
- Coronary artery disease
Who it serves
- Academic medical centers
- Biotech companies
- Clinical laboratories
- Health systems
- Pharmaceutical companies
- Physicians/Clinicians
- Research institutions
Deployment & integration
Cloud Saas · Hybrid deployment with recorded integration context.
Recorded integration context: Clinical laboratory workflows, EHR systems (implied), Illumina, Thermo Fisher Axiom genotyping platform.
Geographic context
MarketsAustralia · Global (multi-ancestry focus) · Taiwan · United States
Company sourceOfficial website
Company milestones
Platform expansion
2026 ACC/AHA guidelines recognition for multi-ancestry CAD PRS; Launch of AbsoluteDx comprehensive genetic test; Commercial license agreement with Cambridge Enterprise; VA partnership for cardiovascular risk study; Launch of Allelica Precision Server for on-premises analysis; Multiple clinical implementation studies initiated
Partnerships
Recorded partners
- Baylor College of Medicine
- Illumina
- Invitae
- SP BioMed (Taiwan)
- Taiwanese biobanks
- Thermo Fisher Scientific
- U.S. Department of Veterans Affairs
- UAB Cardiogenomics Clinic
- University of Cambridge (Cambridge Enterprise)
- University of Sydney
- Yale School of Medicine
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Allelica Precision Server
On-premises bioinformatics platform for CLIA-compliant PRS analysis
Platform · HybridCompany source
Breast Risk Reveal™
Integrated monogenic and polygenic breast cancer risk assessment
Software · Cloud SaaSCompany source
DISCOVER & VALIDATE
PRS trial stratification platform for pharmaceutical and biotech companies
Platform · Cloud SaaSCompany source
PREDICT
Clinical polygenic risk score testing platform
Software · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
No linked records are currently available.
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Cost savings
Health economics study demonstrates cost savings of PRS in heart attack prevention
Risk identification
Identifies people who clinically behave like LDL-C >190 mg/dL even when their LDL-C is not elevated
Trial efficiency
Shortens trial timelines, reduces participant numbers, enables testing more programs within same budget
Baylor College of Medicine
Integration of clinical, multi-ancestry polygenic risk scores
Strategic collaboration to integrate multi-ancestry PRS into clinical practice
Hamilton Cardiology Associates
PRS testing to guide decisions in uncertain cardiology cases
PRS helps guide decisions in uncertain cases, brings clarity to patients with unexplained events, and facilitates personalized discussions about risk
Intermountain Medical Center
Precision prescribing using genetics for statin decisions in cardiology
PRS serves as tie-breaker for clinical decision-making in patients with uncertain risk profiles
Pacific Heart Institute
Proactive heart attack prevention using polygenic risk scoring
Transformed cardiology practice by quantifying genetic contribution to cardiovascular risk with precision not previously accessible
Penn Medicine Center for Preventive Cardiology and Lipid Management
Improving clinical management of cardiovascular disease using PRS testing
Dr. Douglas Jacoby discusses experience prescribing PRS testing and using results to improve clinical management
Scripps Health
PRS in preventive care across cardiovascular disease, Alzheimer's disease, and breast cancer
Four real-world cases illustrating clinical utility of PRS
Stone Oak Women's Center
Combined monogenic and polygenic risk assessment for breast cancer management
Testing made huge difference in understanding individualized risk and supporting confident clinical decisions
U.S. Department of Veterans Affairs
Clinical genomics study aimed at reducing cardiovascular risk in veterans
Partnership to perform clinical genomics study for cardiovascular risk reduction
UAB Cardiogenomics Clinic
Polygenic risk score clinical implementation study
Clinical implementation study for PRS in cardiology
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Allelica
Recent articles published on Allelica's official website.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Precision Medicine & Genomics
Companies using AI to analyze genomic, proteomic, metabolomic, or multi-omics data to provide personalized treatment recommendations, identify genetic risks, or develop targeted therapies. Includes genomic sequencing platforms with AI analysis, preventive medicine based on genetic risk assessment, and longevity care based on molecular and genetic data.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.